



European Directorate for the
Quality of Medicines & HealthCare



Certification of Substances Division

Certificate of suitability
No. R1-CEP 2005-003-Rev 02

1 *Name of the substance:*

2 **PROPOFOL**

3 code number 22270

4 *Name of holder:*

5 **BACHEM S.A.**

6 Succursale de Vionnaz

7 Route du Simplon 22

8 Switzerland-1895 Vionnaz

9 *Site(s) of production:*

10 **BACHEM S.A.**

11 Succursale de Vionnaz

12 Route du Simplon 22

13 Switzerland-1895 Vionnaz

14 **THIS CERTIFICATE SUPERSEDES THE PREVIOUS CERTIFICATE**

15 **R1-CEP 2005-003-REV 01**

16 After examination of the information provided on the manufacturing method and
17 subsequent processes (including purification) for this substance on the site(s) of
18 production mentioned above, we certify that the quality of the substance is suitably
19 controlled by the current version of the monograph **PROPOFOL** no. 1558 of the
20 European Pharmacopoeia, current edition including supplements.

21 The re-test period of the substance is 36 months if stored under nitrogen in
22 aluminium bottles coated with an epoxy phenolic resin, closed with a polypropylene
23 screw cap with Teflon liner.

24 The holder of the certificate has declared the absence of use of material of human or
25 animal origin in the manufacture of the substance.

26 The submitted dossier must be updated after any significant change that may alter the
27 quality, safety or efficacy of the substance.

28 Manufacture of the substance shall take place in accordance with the Good
29 Manufacturing Practice and in accordance with the dossier submitted.

Address: 7, allée Kastner, CS 30026 - F - 67081 Strasbourg (France)
Telephone: 33 (0) 3 88 41 30 30 - Fax: 33 (0) 3 88 41 27 71 - e-mail: cep@edqm.eu
Internet : <http://www.edqm.eu>



NOT VALID FOR REGULATORY PURPOSES

30 Failure to comply with these provisions will render this certificate void.

31 This certificate is renewed from **19 December 2010** according to the provisions of
32 Resolution AP-CSP (93) 5 as amended, and of Directive 2001/83/EC and Directive
33 2001/82/EC and any subsequent amendment, and the related guidelines.

34 This certificate has :
35 lines.



On behalf of the
Director of EDQM



Strasbourg, 8 August 2011

DECLARATION OF ACCESS *(to be filled in by the certificate holder under their own responsibility)*

BACHEM S.A., as holder of the certificate of suitability

R1-CEP 2005-003-Rey 02 for PROPOFOL

hereby authorises
(name of the pharmaceutical company)

to use the above-mentioned certificate of suitability in support of their application(s) for the following
Marketing Authorisation(s): *(name of product(s) and marketing number(s), if known)*

The holder also certifies that no significant changes to the operations as described in the CEP dossier
have been made since the granting of this version of the certificate.

Date and Signature *(of the CEP holder)*:

Address: 7, allée Kastner, CS 30026 - F - 67081 Strasbourg (France)
Telephone: 33 (0) 3 88 41 30 30 - Fax: 33 (0) 3 88 41 27 71 - e-mail: cep@edqm.eu
Internet : <http://www.edqm.eu>



NOT VALID FOR REGULATORY PURPOSES